The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.
about
Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemiaTumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the artUse of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.CD8+ T-cell memory in tumor immunology and immunotherapy.DNA-methylation profiling distinguishes malignant melanomas from benign nevi.MHC class I chain-related gene a diversity in patients with cutaneous malignant melanoma from southeastern Spain.Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.Anti-tumor antibodies in ovarian cancer.Modulation of immune response by B7 family molecules in tumor microenvironments.The role of the CTLA4 blockade in the treatment of malignant melanoma.Targeting the tumor microenvironment by immunotherapy: part 2.Targeting HLA class I expression to increase tumor immunogenicity.Metastatic tumor dormancy in cutaneous melanoma: does surgery induce escape?Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy.Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.Immunotherapy eradicates metastases with reversible defects in MHC class I expression.Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research.DC maturation and function are not altered by melanoma-derived immunosuppressive soluble factors.KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis.Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen.
P2860
Q24800882-4F6C19B3-B81C-4293-A2D4-2B768D157C36Q33907628-E8AE9807-C7B7-4EAF-A582-EA3F26AA7E3AQ34138324-1138AE00-1F25-4E92-BC44-66C8B5B28A3CQ34768139-77F9D291-FDA1-408A-8C54-ADFBEB3642FDQ34775571-E4AF4A29-B03A-4F15-AE70-6CBB29372186Q35207563-4EC3CBF3-0CE7-451D-9798-2AB0FE08203BQ36067524-8ABE36D2-8420-4FD4-941F-CCC0D446A1D8Q36232263-308EEB7D-5375-4587-84E3-B523AD853535Q36569007-D583BA26-BFE4-453F-BA8F-3861E1B918A0Q37008621-F25B4534-25AD-44D6-9CF6-C0E291A31DB2Q37952796-F4B5E84C-C440-4894-800A-74A3BCA20473Q37981721-A47229B6-C7C9-43A8-87F1-4CF8743E2A73Q38161337-84E6C912-EEE2-4A5C-834B-31E9C9428F69Q38253084-6464E7E6-BA8F-4049-A0ED-9CAF3A4B449AQ38394496-959E4A87-FFFD-4997-9D5E-A19AE37BFFE8Q39546174-7A9E5273-26DD-4E63-A96A-A6CA52347C4DQ42017582-3FF28561-95F2-423E-B420-7C169F4CCBD7Q43136973-E205A7AC-EF01-4815-A63F-F3A32AD65DDFQ54273648-B17D0AC3-23FB-4764-948A-835BA65BD49CQ54628562-3B83CC9D-A8AC-41B6-8A95-BD891CD5255B
P2860
The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The paradox of T-cell-mediated ...... cal outcome in human melanoma.
@ast
The paradox of T-cell-mediated ...... cal outcome in human melanoma.
@en
type
label
The paradox of T-cell-mediated ...... cal outcome in human melanoma.
@ast
The paradox of T-cell-mediated ...... cal outcome in human melanoma.
@en
prefLabel
The paradox of T-cell-mediated ...... cal outcome in human melanoma.
@ast
The paradox of T-cell-mediated ...... cal outcome in human melanoma.
@en
P1476
The paradox of T-cell-mediated ...... ical outcome in human melanoma
@en
P2093
Claudia Vegetti
P2888
P304
P356
10.1007/S00262-004-0526-8
P577
2004-06-03T00:00:00Z